ArticleDiscover oncology2026
A study on the association between TP53 Arg72Pro, XRCC1 Arg399Gln, GSTP1 Ile105Val, and GSTM3 indel and the risk of cutaneous squamous cell carcinoma: a systematic review and meta-analysis.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAs one of the most frequent malignancies, cutaneous squamous cell carcinoma (cSCC) exhibits a rising occurrence, imposing a substantial burden on healthcare systems. This meta-analysis unveils the link to cSCC susceptibility of polymorphisms in Tumor Protein p53 (TP53 Arg72Pro, rs1042522), X-ray Repair Cross-Complementation Group 1 (XRCC1 Arg399Gln, rs25487), Glutathione S-Transferase Pi 1 (GSTP1 Ile105Val, rs1695), and the 3-bp insertion/deletion polymorphism in intron 6 of the Glutathione S-Transferase Mu 3 (GSTM3) gene.
methodsPubMed, Embase, Cochrane Library, as well as Web of Science were retrieved systematically to obtain pertinent case-control research until September 2024. The relations of TP53 Arg72Pro, XRCC1 Arg399Gln, GSTP1 Ile105Val, to the GSTM3 intron 6 insertion/deletion polymorphism (hereafter, GSTM3 indel) and cSCC risk were elucidated utilizing odds ratios (ORs) with 95% confidence intervals (CIs) in additive, dominant, recessive, homozygous, heterozygous, as well as allelic models. Heterogeneity was assessed using the Cochrane Q test and the I² statistic. To further explore potential sources of heterogeneity, subgroup analyses were conducted based on geographic region, sample size, source of controls, genotyping methods, and conformity with Hardy-Weinberg equilibrium. The robustness of the results was evaluated through sensitivity analyses. Publication bias was assessed using funnel plots and Egger’s test when ten or more eligible studies were included.
resultsThis meta-analysis revealed no significant association between the TP53 Arg72Pro, XRCC1 Arg399Gln, GSTP1 Ile105Val, and the GSTM3 indel and the risk of cSCC across all genetic models and the risk of cSCC across all genetic models. However, these gene polymorphisms exhibited substantial population heterogeneity and model-dependent associations with cSCC risk. Among the five genetic models, excluding the recessive model, TP53 Arg72Pro polymorphism was associated with an increased cSCC risk in Asian populations. XRCC1 Arg399Gln polymorphism was associated with elevated cSCC risk in European populations under the additive, allelic, and homozygous models, whereas it was associated with a decreased risk in North American populations. Notably, GSTP1 Ile105Val displayed a bidirectional effect in European populations: it was associated with reduced risk under the additive, allelic, and recessive models, but with increased risk under the homozygous model. The GSTM3 indel showed no significant association in any analysis.
conclusionOur findings suggest that TP53 Arg72Pro, XRCC1 Arg399Gln, GSTP1 Ile105Val, and the GSTM3 indel are unlikely to be risk factors for cSCC. Further well-designed case-control studies are warranted to comprehensively assess the potential roles of these four polymorphisms in cSCC susceptibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.